Browse
Submit Data
Databases
API
Help

Dataset Information

4 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

LS_SpikedSerum

ABSTRACT: Latin square spiked serum

INSTRUMENT(S): ABI QSTAR

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Others

SUBMITTER: Olga Vitek, Hui Zhang et al. (ISB)

PROVIDER: PAe000262 | PeptideAtlas |

REPOSITORIES: PeptideAtlas

ACCESS DATA

Json Xml

Similar Datasets

Profiling of antibodies against prostate cancer xenograft-released proteins

2011-12-16 | GSE16220 | GEO

Serum Circulating Proteins from Pediatric Dilated Cardiomyopathy Patients Cause Pathologic Remodeling and Cardiomyocyte Stiffness [SOMA-proteomics]

Project description:Dilated cardiomyopathy (DCM) is the most common form of cardiomyopathy and main indication for heart transplantation in children. Therapies specific to pediatric DCM remains limited due to lack of a disease model. Our previous study showed that treatment of neonatal rat ventricular myocytes (NRVMs) with non-failing or DCM pediatric patient serum activates the fetal gene program (FGP). Here we show that serum treatment with Proteinase K prevents activation of the FGP, whereas RNase treatment exacerbates it, suggesting that circulating proteins, but not circulating microRNAs, promote these pathological changes. Evaluation of the protein secretome showed that midkine (MDK) is up-regulated in DCM serum, and NRVM treatment with MDK activates the FGP. Changes in gene expression in serum-treated NRVMs, evaluated by next-generation RNA sequencing (RNA-Seq), indicates extracellular matrix remodeling and focal adhesion pathways are upregulated in pediatric DCM serum and serum-treated NRVMs, suggesting alterations in cellular stiffness. Cellular stiffness was evaluated by Atomic Force Microscopy, which showed an increase in stiffness in DCM serum-treated NRVMs. Of the proteins increased in DCM sera, secreted frizzled related protein 1 (sFRP1) was a potential candidate for the increase in cellular stiffness, and sFRP1 treatment of NRVMs recapitulated the increase in cellular stiffness observed in response to DCM-serum treatment. Our results show that serum circulating proteins promote pathological changes in gene expression and cellular stiffness, and circulating miRNAs are protective against pathological changes.

2021-07-31 | GSE181091 | GEO

Longitudinal serum auto-antibody response during HER2-CAR T cell therapy in a child with rhabdomyosarcoma identified using Protein microarray

Project description:Protein microarray was used to identify proteins with elevated interactions with serum autoantibodies in a responding patient with rhabdomyosarcoma before and after multiple doses of HER2 CAR T cell therapy. Elevated signals were observed for multiple proteins interacting with serum autoantibodies following multiple doses of HER2-CAR T cell treatment when compared to pre-treatment serum.

2020-06-09 | GSE152029 | GEO

Human serum: Control vs. Lung Cancer

Project description:The autoantibodies in serum (IgG antibody labeled with Cy3 and IgM antibody labeled with Cy5) were quantified by serum incubation human protein microarray, and the data of normal people and lung cancer patients were compared to find the predictive markers of autoantibodies in lung cancer

2024-03-02 | GSE168198 | GEO

Profiling of antibodies against prostate cancer xenograft-released proteins

Project description:The present study describes a novel xenograft-based biomarker discovery platform and proves its usefulness in the discovery of novel serum markers for prostate cancer (PCa). By immunizing immuno-competent mice with serum from nude mice bearing PCa xenografts, an antibody response against xenograft-derived antigens was elicited. By probing protein microarrays with serum from immunized mice, several PCa-derived antigens were identified, of which a subset was successfully retrieved in serum from mice bearing PCa xenografts and validated in human serum samples of PCa patients. In conclusion, this novel method allows for the identification of low abundant cancer-derived serum proteins, circumventing dynamic range and host-response issues in standard patient cohort proteomics comparisons. To perform a large-scale identification of antibodies generated against human PCa-derived proteins in the serum of immunized mice, sera from mice immunized with either depleted serum, full serum or both from PC346 and PC339-bearing mice as well as preimmune serum and serum from mice immunized with normal mouse serum were incubated onto ProtoArrays. These ProtoArrays contain approximately 8,000 partial and full-length human proteins, expressed as N-terminal glutathione S-transferase (GST) fusion proteins. To detect antibodies bound to spotted proteins, ProtoArrays were developed using a fluorescent labeled secondary antibody. Before being used for immunization, serum from xenografted mice was not treated (full) or depleted for most abundant proteins (depleted). Two arrays were hybridized with pre-immune serum and one array with serum from an immune competent mouse that was immunized with serum from a nude mouse. Six arrays were performed using serum from immune competent mice that were immunized with serum from xenograft-bearing nude mice.

2011-12-16 | E-GEOD-16220 | biostudies-arrayexpress

E-PROT-109

Project description:Molecular composition of serum exosomes

2023-06-21 | E-PROT-109 | ExpressionAtlas

Alterations to the Hidradenitis Suppurativa Serum Proteome with Spleen Tyrosine Kinase Antagonism: Proteomic Results from a Phase 2 Clinical Trial.

Project description:Serum Proteomic Analysis of patients with Hidradenitis Suppurativa treated with Fostamatinib

2023-08-10 | GSE240607 | GEO

Differences in bone marrow serum proteins in acute myeloid leukemia patients and normal controls

Project description:we evaluated cytokine profiling of bone marrow serum samples in AML patients and healthy controls. Protein expression profiling of serum from 9 AML patients and 5 healthy controls was obtained using biotinylated antibody chip. Total 507 cytokines and growth factors were analyzed. Compared with healthy people, AML patients expressed 31 signature proteins, among which, 27 were found significantly higher expressed and 4 proteins were lower.

2019-12-17 | GSE141930 | GEO

Rapid Attenuation of B-Cell and Interferon Gamma Associated Chemokines in Clinical Responders to Janus Kinase Inhibition with Upadacitinib in Hidradenitis Suppurativa II.

Project description:Serum Proteomic Analysis of patients with Pyoderma Gangrenosum Treated with Tildrakizumab 200mg q4weekly for 12 weeks

2023-08-18 | GSE241085 | GEO

Comparison of protein profiles in the serum of NPC patients with different prognosis by high-throughput protein microarrays

Project description:High levels of c-Src in serum of patients with NPC was independent prognostic indicators for poor outcome of patients.

2015-05-12 | GSE68764 | GEO